Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 5
1999 1
2001 1
2002 1
2003 2
2006 1
2008 2
2009 3
2010 4
2011 5
2012 3
2013 4
2014 2
2015 5
2016 3
2017 3
2018 7
2019 8
2020 9
2021 4
2022 4
2023 6
2024 7
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Green JB, et al. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. N Engl J Med. 2015. PMID: 26052984 Free article. Clinical Trial.
Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study.
Park HK, Kim KA, Min KW, Sohn TS, Jeong IK, Ahn CW, Kim NH, Park IB, Cho HC, Chung CH, Choi SH, Park KS, Yang SO, Lee KW. Park HK, et al. Among authors: park ib. Diabetes Obes Metab. 2023 Sep;25(9):2743-2755. doi: 10.1111/dom.15164. Epub 2023 Jun 20. Diabetes Obes Metab. 2023. PMID: 37337747 Clinical Trial.
Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Kim MK, Rhee EJ, Han KA, Woo AC, Lee MK, Ku BJ, Chung CH, Kim KA, Lee HW, Park IB, Park JY, Chul Jang HC, Park KS, Jang WI, Cha BY. Kim MK, et al. Among authors: park ib. Diabetes Obes Metab. 2015 Mar;17(3):309-12. doi: 10.1111/dom.12424. Epub 2015 Jan 18. Diabetes Obes Metab. 2015. PMID: 25475929 Free PMC article. Clinical Trial.
89 results